Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood ... the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon ...

Biotech-stock investing has one tough test for success - and it's about to get easier ...

Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical ... and difficulties with speech. The disease is so rare, ...

Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...